No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 43.9x · 10Y median 57.4x · 35th percentile · as of Oct 6, 2026
Annual revenue · last 1 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:28:31.032Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for TAO Synergies Inc. (TAOX) stock was $4.54 as of Oct 6, 2026, 2:25 PM EDT, up 2.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -30.8%
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage.
Software - Application · New York, NY
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-12.75
Revenue Est.
$88626.00
Last Quarter Results
EPS
$-1.83
vs Estimate
$-12.75
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TAOX | $33.91M | $4.54 | +2.43% | -30.77% | N/A | N/A | N/A |
| 2MLGO | $33.75M | $3.08 | -2.99% | -69.07% | -86.05% | N/A | vs TAOX |
| 3RPGL | $34.30M | $34.05 | -1.02% | N/A | N/A | N/A | vs TAOX |
| 4SLMT | $33.14M | $3.95 | +1.02% | -98.38% | N/A | N/A | vs TAOX |
| 5BRAG | $34.74M | $1.14 | -1.72% | -59.82% | -34.95% | N/A | vs TAOX |
| 6BOSC | $32.78M | $4.65 | +0.22% | -2.51% | +7.78% | +7.75% | vs TAOX |
forward FY estimate
N/A
$88626.00
vs Estimate
$88626.00
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.54
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-12.75 | $-12.75 | $-12.75 | 1 |
| Quarter ending Dec 2026 | $-12.75 | $-12.75 | $-12.75 | 1 |
| Quarter ending Mar 2027 | $-12.00 | $-12.00 | $-12.00 | 1 |
| Quarter ending Jun 2027 | $-13.75 | $-13.75 | $-13.75 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-7.03 | $-7.03 | $-7.03 | 1 |
| FY 2027 | $-7.44 | $-7.44 | $-7.44 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $88626.00 | $88626.00 | $88626.00 | 1 |
| Quarter ending Dec 2026 | $88626.00 | $88626.00 | $88626.00 | 1 |
| Quarter ending Mar 2027 | $88626.00 | $88626.00 | $88626.00 | 1 |
| Quarter ending Jun 2027 | $88626.00 | $88626.00 | $88626.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $41.74M | $41.74M | $41.74M | 1 |
| FY 2027 | $299061.00 | $299061.00 | $299061.00 | 1 |
